Cargando…
Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test
INTRODUCTION: Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidies using cell-free DNA (cfDNA) has been widely adopted in clinical practice due to its improved accuracy. A number of NIPT tests have been developed and validated. The purpose of this study is to evaluate the performance of the V...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628499/ https://www.ncbi.nlm.nih.gov/pubmed/31338126 http://dx.doi.org/10.1186/s13039-019-0446-0 |
_version_ | 1783434974389600256 |
---|---|
author | Kypri, Elena Ioannides, Marios Touvana, Evi Neophytou, Ioanna Mina, Petros Velissariou, Voula Vittas, Spiros Santana, Alfredo Alexidis, Filippos Tsangaras, Kyriakos Achilleos, Achilleas Patsalis, Philippos Koumbaris, George |
author_facet | Kypri, Elena Ioannides, Marios Touvana, Evi Neophytou, Ioanna Mina, Petros Velissariou, Voula Vittas, Spiros Santana, Alfredo Alexidis, Filippos Tsangaras, Kyriakos Achilleos, Achilleas Patsalis, Philippos Koumbaris, George |
author_sort | Kypri, Elena |
collection | PubMed |
description | INTRODUCTION: Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidies using cell-free DNA (cfDNA) has been widely adopted in clinical practice due to its improved accuracy. A number of NIPT tests have been developed and validated. The purpose of this study is to evaluate the performance of the Veracity NIPT test for sex chromosome aneuploidy (SCA) detection in singleton pregnancies, autosomal aneuploidy detection in twin pregnancies and evaluation of Veracity clinical performance under routine NIPT conditions in a diverse cohort. METHODS: Blinded retrospective study in singleton pregnancies (n = 305); blinded retrospective and prospective study in twin pregnancies (n = 306) and prospective evaluation of clinical performance in singleton and twin pregnancies (n = 10564). RESULTS: Validation study results for the detection of SCAs in singleton pregnancies exhibited 100% sensitivity and specificity and correctly classified 7 (45,X), 4 (47,XXY), 2 (47,XXX) and 1 (47,XYY) cases. Validation study results for autosomal aneuploidy detection in twin pregnancies exhibited 100% sensitivity and specificity and correctly classified 3 trisomy 21, 1 trisomy 18 and 1 trisomy 13 samples. Clinical performance evaluation of Veracity was performed in 10564 pregnancies with median gestational age of 13 weeks, median maternal age 35 years and median gestational weight of 64 kg. Based on confirmation feedback the PPV for trisomies 21, 18 and 13 was estimated at 100% (95% CI, 92–100%), 100% (95% CI, 69–100%) and 71% (95% CI, 29–96%), respectively. Estimated PPV for Monosomy X was 57% (95%CI, 18–90%), while the NPV for SCA detection was estimated at 100% (95% CI, 99.94–100%). CONCLUSION: Veracity NIPT test is based on a very powerful, highly accurate methodology that can be safely applied in the clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13039-019-0446-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6628499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66284992019-07-23 Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test Kypri, Elena Ioannides, Marios Touvana, Evi Neophytou, Ioanna Mina, Petros Velissariou, Voula Vittas, Spiros Santana, Alfredo Alexidis, Filippos Tsangaras, Kyriakos Achilleos, Achilleas Patsalis, Philippos Koumbaris, George Mol Cytogenet Research INTRODUCTION: Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidies using cell-free DNA (cfDNA) has been widely adopted in clinical practice due to its improved accuracy. A number of NIPT tests have been developed and validated. The purpose of this study is to evaluate the performance of the Veracity NIPT test for sex chromosome aneuploidy (SCA) detection in singleton pregnancies, autosomal aneuploidy detection in twin pregnancies and evaluation of Veracity clinical performance under routine NIPT conditions in a diverse cohort. METHODS: Blinded retrospective study in singleton pregnancies (n = 305); blinded retrospective and prospective study in twin pregnancies (n = 306) and prospective evaluation of clinical performance in singleton and twin pregnancies (n = 10564). RESULTS: Validation study results for the detection of SCAs in singleton pregnancies exhibited 100% sensitivity and specificity and correctly classified 7 (45,X), 4 (47,XXY), 2 (47,XXX) and 1 (47,XYY) cases. Validation study results for autosomal aneuploidy detection in twin pregnancies exhibited 100% sensitivity and specificity and correctly classified 3 trisomy 21, 1 trisomy 18 and 1 trisomy 13 samples. Clinical performance evaluation of Veracity was performed in 10564 pregnancies with median gestational age of 13 weeks, median maternal age 35 years and median gestational weight of 64 kg. Based on confirmation feedback the PPV for trisomies 21, 18 and 13 was estimated at 100% (95% CI, 92–100%), 100% (95% CI, 69–100%) and 71% (95% CI, 29–96%), respectively. Estimated PPV for Monosomy X was 57% (95%CI, 18–90%), while the NPV for SCA detection was estimated at 100% (95% CI, 99.94–100%). CONCLUSION: Veracity NIPT test is based on a very powerful, highly accurate methodology that can be safely applied in the clinical setting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13039-019-0446-0) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-15 /pmc/articles/PMC6628499/ /pubmed/31338126 http://dx.doi.org/10.1186/s13039-019-0446-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Kypri, Elena Ioannides, Marios Touvana, Evi Neophytou, Ioanna Mina, Petros Velissariou, Voula Vittas, Spiros Santana, Alfredo Alexidis, Filippos Tsangaras, Kyriakos Achilleos, Achilleas Patsalis, Philippos Koumbaris, George Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test |
title | Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test |
title_full | Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test |
title_fullStr | Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test |
title_full_unstemmed | Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test |
title_short | Non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test |
title_sort | non-invasive prenatal testing of fetal chromosomal aneuploidies: validation and clinical performance of the veracity test |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628499/ https://www.ncbi.nlm.nih.gov/pubmed/31338126 http://dx.doi.org/10.1186/s13039-019-0446-0 |
work_keys_str_mv | AT kyprielena noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT ioannidesmarios noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT touvanaevi noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT neophytouioanna noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT minapetros noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT velissariouvoula noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT vittasspiros noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT santanaalfredo noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT alexidisfilippos noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT tsangaraskyriakos noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT achilleosachilleas noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT patsalisphilippos noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest AT koumbarisgeorge noninvasiveprenataltestingoffetalchromosomalaneuploidiesvalidationandclinicalperformanceoftheveracitytest |